Efficacy and Safety of Natalizumab in Multiple Sclerosis: Interim Observational Program Results from an Australian Cohort

H. Butzkueven, M. Barnett, S. Broadley, S. Hodgkinson, J. King, C. Kneebone, M. Slee, J. Lechner-Scott, A. Kermode, N. Shuey, R. Macdonell, Y. Chen, K. Naidoo, H. Koendgen

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)419-420
JournalMultiple Sclerosis Journal
Volume22
Issue number3
Publication statusPublished - 2016

Cite this